ºÝºÝߣshows by User: MarcAnders2 / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: MarcAnders2 / Fri, 26 Jun 2020 01:24:55 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: MarcAnders2 ANEMIA IS ASSOCIATED WITH GREATER MORBIDITY AND RESOURCE UTILIZATION IN PEDIATRIC PATIENTS WITH SYSTOLIC HEART FAILURE: A MULTI-INSTITUTIONAL ANALYSIS /slideshow/anemia-is-associated-with-greater-morbidity-and-resource-utilization-in-pediatric-patients-with-systolic-heart-failure-a-multiinstitutional-analysis/236228267 ishltposter-200626012455
Design: Retrospective cohort study querying the Pediatric Health Information System (PHIS) database, comprised of 50 children’s hospitals over 10 years (01/2008 to 12/2017). Admissions of patients aged < 21 years (yr) with ICD-9/10 codes for systolic HF were included. Patients with congenital heart disease (CHD) codes were excluded to avoid confounding by polycythemia due to cyanotic CHD. Demographic and clinical features and procedures during admission reviewed using ICD-9/10 coding. Outcomes: Primary outcome was composite cardiac death (CCD, defined as ventricular assist device (VAD), heart transplant (HTx), or death during admission), and the secondary outcomes were hospital length of stay (LOS) and billed charges. Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering by hospitals - factors with p<0.2 on univariate analysis included in the initial multivariable model, and factors with p<0.05 retained in successive models. In a hospital admission of a pediatric patient with systolic HF without CHD, anemia is associated with more systemic comorbidities, and greater resource utilization (longer LOS and higher billed charges). This suggests a need for examining anemia management strategies to optimize pediatric HF outcomes. [03/2019]]]>
Design: Retrospective cohort study querying the Pediatric Health Information System (PHIS) database, comprised of 50 children’s hospitals over 10 years (01/2008 to 12/2017). Admissions of patients aged < 21 years (yr) with ICD-9/10 codes for systolic HF were included. Patients with congenital heart disease (CHD) codes were excluded to avoid confounding by polycythemia due to cyanotic CHD. Demographic and clinical features and procedures during admission reviewed using ICD-9/10 coding. Outcomes: Primary outcome was composite cardiac death (CCD, defined as ventricular assist device (VAD), heart transplant (HTx), or death during admission), and the secondary outcomes were hospital length of stay (LOS) and billed charges. Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering by hospitals - factors with p<0.2 on univariate analysis included in the initial multivariable model, and factors with p<0.05 retained in successive models. In a hospital admission of a pediatric patient with systolic HF without CHD, anemia is associated with more systemic comorbidities, and greater resource utilization (longer LOS and higher billed charges). This suggests a need for examining anemia management strategies to optimize pediatric HF outcomes. [03/2019]]]> Fri, 26 Jun 2020 01:24:55 GMT /slideshow/anemia-is-associated-with-greater-morbidity-and-resource-utilization-in-pediatric-patients-with-systolic-heart-failure-a-multiinstitutional-analysis/236228267 MarcAnders2@slideshare.net(MarcAnders2) ANEMIA IS ASSOCIATED WITH GREATER MORBIDITY AND RESOURCE UTILIZATION IN PEDIATRIC PATIENTS WITH SYSTOLIC HEART FAILURE: A MULTI-INSTITUTIONAL ANALYSIS MarcAnders2 Design: Retrospective cohort study querying the Pediatric Health Information System (PHIS) database, comprised of 50 children’s hospitals over 10 years (01/2008 to 12/2017). Admissions of patients aged < 21 years (yr) with ICD-9/10 codes for systolic HF were included. Patients with congenital heart disease (CHD) codes were excluded to avoid confounding by polycythemia due to cyanotic CHD. Demographic and clinical features and procedures during admission reviewed using ICD-9/10 coding. Outcomes: Primary outcome was composite cardiac death (CCD, defined as ventricular assist device (VAD), heart transplant (HTx), or death during admission), and the secondary outcomes were hospital length of stay (LOS) and billed charges. Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering by hospitals - factors with p<0.2 on univariate analysis included in the initial multivariable model, and factors with p<0.05 retained in successive models. In a hospital admission of a pediatric patient with systolic HF without CHD, anemia is associated with more systemic comorbidities, and greater resource utilization (longer LOS and higher billed charges). This suggests a need for examining anemia management strategies to optimize pediatric HF outcomes. [03/2019] <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ishltposter-200626012455-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Design: Retrospective cohort study querying the Pediatric Health Information System (PHIS) database, comprised of 50 children’s hospitals over 10 years (01/2008 to 12/2017). Admissions of patients aged &lt; 21 years (yr) with ICD-9/10 codes for systolic HF were included. Patients with congenital heart disease (CHD) codes were excluded to avoid confounding by polycythemia due to cyanotic CHD. Demographic and clinical features and procedures during admission reviewed using ICD-9/10 coding. Outcomes: Primary outcome was composite cardiac death (CCD, defined as ventricular assist device (VAD), heart transplant (HTx), or death during admission), and the secondary outcomes were hospital length of stay (LOS) and billed charges. Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering by hospitals - factors with p&lt;0.2 on univariate analysis included in the initial multivariable model, and factors with p&lt;0.05 retained in successive models. In a hospital admission of a pediatric patient with systolic HF without CHD, anemia is associated with more systemic comorbidities, and greater resource utilization (longer LOS and higher billed charges). This suggests a need for examining anemia management strategies to optimize pediatric HF outcomes. [03/2019]
ANEMIA IS ASSOCIATED WITH GREATER MORBIDITY AND RESOURCE UTILIZATION IN PEDIATRIC PATIENTS WITH SYSTOLIC HEART FAILURE: A MULTI-INSTITUTIONAL ANALYSIS from Texas Children's Hospital
]]> 162 0 https://cdn.slidesharecdn.com/ss_thumbnails/ishltposter-200626012455-thumbnail.jpg?width=120&height=120&fit=bounds infographic Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 ECMO in peripartum cardiomyopathy - an ELSO review /slideshow/ecmo-in-peripartum-cardiomyopathy-an-elso-review/133728440 ppcmposterdraft2ma-190228185021
* Taylor, Olson, Marc, Anders Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy characterized by heart failure secondary to left ventricular systolic dysfunction, typically with an ejection fraction <45%, occurring towards the end of pregnancy or in the months following delivery for which no other cause of heart failure is found.1 Rarely, catastrophic presentations can occur with severe respiratory distress and low cardiac output necessitating mechanical ventilation and circulatory support. Data on the use of extracorporeal membrane oxygenation (ECMO) in PPCM is limited. Little is known about the safety, efficacy, or mortality. The Extracorporeal Life Support Organization (ELSO) maintains an international registry of patients treated with ECMO since 1989 and collects data from over 300 pediatric and adult centers. We sought to examine the ELSO registry for PPCM patients treated with ECMO in order to characterize demographic and clinical features, complications, overall survival to discharge, and variables associated with mortality. 46 patients met inclusion criteria. 2 patients were excluded leaving 44 patients for the analysis. Overall survival to discharge was 56.8% while 75.0% of patients were weaned off ECMO. All patients had one ECMO run except for one patient who had two. All patients were conventionally ventilated. Cardiovascular (52.3%), renal (36.4%), hemorrhagic (34.1%), mechanical (25.0%), infectious (15.9%), metabolic (15.9%), neurologic (11.4%), and pulmonary (9.1%) complications were reported. Pre- ECMO variables associated with decreased survival included higher ventilation rate (p=0.03**, OR 0.88 [0.79-0.98]) and support with vasopressor or inotropic agents (p<0.01, OR 0.09 [0.01-0.82]). Decreased survival was also observed in patients with ECMO cannula site bleeding (p=0.02, OR 0.14 [0.02-0.83]). Our review is the largest to date of PPCM patients supported with ECMO. We identified factors associated with mortality including pre-ECMO ventilation rate, pre-ECMO support with vasopressors, and ECMO cannula site bleeding. We believe our data supports the use of ECMO in PPCM when clinically indicated. ]]>
* Taylor, Olson, Marc, Anders Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy characterized by heart failure secondary to left ventricular systolic dysfunction, typically with an ejection fraction <45%, occurring towards the end of pregnancy or in the months following delivery for which no other cause of heart failure is found.1 Rarely, catastrophic presentations can occur with severe respiratory distress and low cardiac output necessitating mechanical ventilation and circulatory support. Data on the use of extracorporeal membrane oxygenation (ECMO) in PPCM is limited. Little is known about the safety, efficacy, or mortality. The Extracorporeal Life Support Organization (ELSO) maintains an international registry of patients treated with ECMO since 1989 and collects data from over 300 pediatric and adult centers. We sought to examine the ELSO registry for PPCM patients treated with ECMO in order to characterize demographic and clinical features, complications, overall survival to discharge, and variables associated with mortality. 46 patients met inclusion criteria. 2 patients were excluded leaving 44 patients for the analysis. Overall survival to discharge was 56.8% while 75.0% of patients were weaned off ECMO. All patients had one ECMO run except for one patient who had two. All patients were conventionally ventilated. Cardiovascular (52.3%), renal (36.4%), hemorrhagic (34.1%), mechanical (25.0%), infectious (15.9%), metabolic (15.9%), neurologic (11.4%), and pulmonary (9.1%) complications were reported. Pre- ECMO variables associated with decreased survival included higher ventilation rate (p=0.03**, OR 0.88 [0.79-0.98]) and support with vasopressor or inotropic agents (p<0.01, OR 0.09 [0.01-0.82]). Decreased survival was also observed in patients with ECMO cannula site bleeding (p=0.02, OR 0.14 [0.02-0.83]). Our review is the largest to date of PPCM patients supported with ECMO. We identified factors associated with mortality including pre-ECMO ventilation rate, pre-ECMO support with vasopressors, and ECMO cannula site bleeding. We believe our data supports the use of ECMO in PPCM when clinically indicated. ]]> Thu, 28 Feb 2019 18:50:21 GMT /slideshow/ecmo-in-peripartum-cardiomyopathy-an-elso-review/133728440 MarcAnders2@slideshare.net(MarcAnders2) ECMO in peripartum cardiomyopathy - an ELSO review MarcAnders2 * Taylor, Olson, Marc, Anders Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy characterized by heart failure secondary to left ventricular systolic dysfunction, typically with an ejection fraction <45%, occurring towards the end of pregnancy or in the months following delivery for which no other cause of heart failure is found.1 Rarely, catastrophic presentations can occur with severe respiratory distress and low cardiac output necessitating mechanical ventilation and circulatory support. Data on the use of extracorporeal membrane oxygenation (ECMO) in PPCM is limited. Little is known about the safety, efficacy, or mortality. The Extracorporeal Life Support Organization (ELSO) maintains an international registry of patients treated with ECMO since 1989 and collects data from over 300 pediatric and adult centers. We sought to examine the ELSO registry for PPCM patients treated with ECMO in order to characterize demographic and clinical features, complications, overall survival to discharge, and variables associated with mortality. 46 patients met inclusion criteria. 2 patients were excluded leaving 44 patients for the analysis. Overall survival to discharge was 56.8% while 75.0% of patients were weaned off ECMO. All patients had one ECMO run except for one patient who had two. All patients were conventionally ventilated. Cardiovascular (52.3%), renal (36.4%), hemorrhagic (34.1%), mechanical (25.0%), infectious (15.9%), metabolic (15.9%), neurologic (11.4%), and pulmonary (9.1%) complications were reported. Pre- ECMO variables associated with decreased survival included higher ventilation rate (p=0.03**, OR 0.88 [0.79-0.98]) and support with vasopressor or inotropic agents (p<0.01, OR 0.09 [0.01-0.82]). Decreased survival was also observed in patients with ECMO cannula site bleeding (p=0.02, OR 0.14 [0.02-0.83]). Our review is the largest to date of PPCM patients supported with ECMO. We identified factors associated with mortality including pre-ECMO ventilation rate, pre-ECMO support with vasopressors, and ECMO cannula site bleeding. We believe our data supports the use of ECMO in PPCM when clinically indicated. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ppcmposterdraft2ma-190228185021-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> * Taylor, Olson, Marc, Anders Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy characterized by heart failure secondary to left ventricular systolic dysfunction, typically with an ejection fraction &lt;45%, occurring towards the end of pregnancy or in the months following delivery for which no other cause of heart failure is found.1 Rarely, catastrophic presentations can occur with severe respiratory distress and low cardiac output necessitating mechanical ventilation and circulatory support. Data on the use of extracorporeal membrane oxygenation (ECMO) in PPCM is limited. Little is known about the safety, efficacy, or mortality. The Extracorporeal Life Support Organization (ELSO) maintains an international registry of patients treated with ECMO since 1989 and collects data from over 300 pediatric and adult centers. We sought to examine the ELSO registry for PPCM patients treated with ECMO in order to characterize demographic and clinical features, complications, overall survival to discharge, and variables associated with mortality. 46 patients met inclusion criteria. 2 patients were excluded leaving 44 patients for the analysis. Overall survival to discharge was 56.8% while 75.0% of patients were weaned off ECMO. All patients had one ECMO run except for one patient who had two. All patients were conventionally ventilated. Cardiovascular (52.3%), renal (36.4%), hemorrhagic (34.1%), mechanical (25.0%), infectious (15.9%), metabolic (15.9%), neurologic (11.4%), and pulmonary (9.1%) complications were reported. Pre- ECMO variables associated with decreased survival included higher ventilation rate (p=0.03**, OR 0.88 [0.79-0.98]) and support with vasopressor or inotropic agents (p&lt;0.01, OR 0.09 [0.01-0.82]). Decreased survival was also observed in patients with ECMO cannula site bleeding (p=0.02, OR 0.14 [0.02-0.83]). Our review is the largest to date of PPCM patients supported with ECMO. We identified factors associated with mortality including pre-ECMO ventilation rate, pre-ECMO support with vasopressors, and ECMO cannula site bleeding. We believe our data supports the use of ECMO in PPCM when clinically indicated.
ECMO in peripartum cardiomyopathy - an ELSO review from Texas Children's Hospital
]]> 155 4 https://cdn.slidesharecdn.com/ss_thumbnails/ppcmposterdraft2ma-190228185021-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Use of inotropic and vasoconstrictor medications in the pediatric heart failure population /slideshow/use-of-inotropic-and-vasoconstrictor-medications-in-the-pediatric-heart-failure-population/132796111 ivmeds-190221222259
* Raysa Morales-Demori, MD Inotropes and vasoconstrictor medications are frequently used in the pediatric heart failure population for the acute and chronic management in this condition; however certain agents, such as Dobutamine, have been associated with increased inpatient mortality Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Dobutamine and Dopamine use has fallen out of favor in the pediatric HF population Dobutamine and Norepinephrine have the highest odds ratio of inpatient mortality ]]>
* Raysa Morales-Demori, MD Inotropes and vasoconstrictor medications are frequently used in the pediatric heart failure population for the acute and chronic management in this condition; however certain agents, such as Dobutamine, have been associated with increased inpatient mortality Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Dobutamine and Dopamine use has fallen out of favor in the pediatric HF population Dobutamine and Norepinephrine have the highest odds ratio of inpatient mortality ]]> Thu, 21 Feb 2019 22:22:59 GMT /slideshow/use-of-inotropic-and-vasoconstrictor-medications-in-the-pediatric-heart-failure-population/132796111 MarcAnders2@slideshare.net(MarcAnders2) Use of inotropic and vasoconstrictor medications in the pediatric heart failure population MarcAnders2 * Raysa Morales-Demori, MD Inotropes and vasoconstrictor medications are frequently used in the pediatric heart failure population for the acute and chronic management in this condition; however certain agents, such as Dobutamine, have been associated with increased inpatient mortality Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Dobutamine and Dopamine use has fallen out of favor in the pediatric HF population Dobutamine and Norepinephrine have the highest odds ratio of inpatient mortality <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ivmeds-190221222259-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> * Raysa Morales-Demori, MD Inotropes and vasoconstrictor medications are frequently used in the pediatric heart failure population for the acute and chronic management in this condition; however certain agents, such as Dobutamine, have been associated with increased inpatient mortality Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Dobutamine and Dopamine use has fallen out of favor in the pediatric HF population Dobutamine and Norepinephrine have the highest odds ratio of inpatient mortality
Use of inotropic and vasoconstrictor medications in the pediatric heart failure population from Texas Children's Hospital
]]> 109 2 https://cdn.slidesharecdn.com/ss_thumbnails/ivmeds-190221222259-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Rethinking digoxin in pediatric heart failure /MarcAnders2/rethinking-digoxin-in-pediatric-heart-failure digoxinpresentation-190221221946
* Raysa Morales-Demori, MD Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Digoxin use was associated with decreased inpatient mortality In patients with CHD (24% vs 76%, p<0.001) In Extreme Risk of Mortality (17% vs 83%, p<0.001) ]]>
* Raysa Morales-Demori, MD Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Digoxin use was associated with decreased inpatient mortality In patients with CHD (24% vs 76%, p<0.001) In Extreme Risk of Mortality (17% vs 83%, p<0.001) ]]> Thu, 21 Feb 2019 22:19:46 GMT /MarcAnders2/rethinking-digoxin-in-pediatric-heart-failure MarcAnders2@slideshare.net(MarcAnders2) Rethinking digoxin in pediatric heart failure MarcAnders2 * Raysa Morales-Demori, MD Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Digoxin use was associated with decreased inpatient mortality In patients with CHD (24% vs 76%, p<0.001) In Extreme Risk of Mortality (17% vs 83%, p<0.001) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/digoxinpresentation-190221221946-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> * Raysa Morales-Demori, MD Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: 01/2004 – 12/2017 Inclusion criteria: All patients ≤ 21 year Heart failure diagnoses ICD-9 (428.xx) or ICD-10 (i50.xx) Digoxin use was associated with decreased inpatient mortality In patients with CHD (24% vs 76%, p&lt;0.001) In Extreme Risk of Mortality (17% vs 83%, p&lt;0.001)
Rethinking digoxin in pediatric heart failure from Texas Children's Hospital
]]> 111 4 https://cdn.slidesharecdn.com/ss_thumbnails/digoxinpresentation-190221221946-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Relative Hyperoxia in cyanotic congenital heart disease on veno-arterial ECMO is associated with decreased survival to hospital discharge - Keystone 2018 /slideshow/relative-hyperoxia-in-cyanotic-congenital-heart-disease-on-venoarterial-ecmo-is-associated-with-decreased-survival-to-hospital-discharge-keystone-2018/127361834 elsoabstractposter-final-190106022506
Extracorporeal membrane oxygenation (ECMO) is an established intervention for respiratory or cardiorespiratory support in children with congenital heart disease (CHD) when all other interventions have failed. Hyperoxia following successful resuscitation has been associated with increased mortality in pediatric and adult studies, including, specifically, hyperoxia during ECMO management. We hypothesized that this effect may be pronounced in patients with lower arterial oxygen saturation at baseline, such as those with cyanotic CHD. We aimed to determine if relative hyperoxia in children with cyanotic single ventricle circulation on Veno-Arterial (VA)- ECMO is a risk factor for mortality in a large multicenter registry analysis.]]>
Extracorporeal membrane oxygenation (ECMO) is an established intervention for respiratory or cardiorespiratory support in children with congenital heart disease (CHD) when all other interventions have failed. Hyperoxia following successful resuscitation has been associated with increased mortality in pediatric and adult studies, including, specifically, hyperoxia during ECMO management. We hypothesized that this effect may be pronounced in patients with lower arterial oxygen saturation at baseline, such as those with cyanotic CHD. We aimed to determine if relative hyperoxia in children with cyanotic single ventricle circulation on Veno-Arterial (VA)- ECMO is a risk factor for mortality in a large multicenter registry analysis.]]> Sun, 06 Jan 2019 02:25:06 GMT /slideshow/relative-hyperoxia-in-cyanotic-congenital-heart-disease-on-venoarterial-ecmo-is-associated-with-decreased-survival-to-hospital-discharge-keystone-2018/127361834 MarcAnders2@slideshare.net(MarcAnders2) Relative Hyperoxia in cyanotic congenital heart disease on veno-arterial ECMO is associated with decreased survival to hospital discharge - Keystone 2018 MarcAnders2 Extracorporeal membrane oxygenation (ECMO) is an established intervention for respiratory or cardiorespiratory support in children with congenital heart disease (CHD) when all other interventions have failed. Hyperoxia following successful resuscitation has been associated with increased mortality in pediatric and adult studies, including, specifically, hyperoxia during ECMO management. We hypothesized that this effect may be pronounced in patients with lower arterial oxygen saturation at baseline, such as those with cyanotic CHD. We aimed to determine if relative hyperoxia in children with cyanotic single ventricle circulation on Veno-Arterial (VA)- ECMO is a risk factor for mortality in a large multicenter registry analysis. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/elsoabstractposter-final-190106022506-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Extracorporeal membrane oxygenation (ECMO) is an established intervention for respiratory or cardiorespiratory support in children with congenital heart disease (CHD) when all other interventions have failed. Hyperoxia following successful resuscitation has been associated with increased mortality in pediatric and adult studies, including, specifically, hyperoxia during ECMO management. We hypothesized that this effect may be pronounced in patients with lower arterial oxygen saturation at baseline, such as those with cyanotic CHD. We aimed to determine if relative hyperoxia in children with cyanotic single ventricle circulation on Veno-Arterial (VA)- ECMO is a risk factor for mortality in a large multicenter registry analysis.
Relative Hyperoxia in cyanotic congenital heart disease on veno-arterial ECMO is associated with decreased survival to hospital discharge - Keystone 2018 from Texas Children's Hospital
]]> 129 2 https://cdn.slidesharecdn.com/ss_thumbnails/elsoabstractposter-final-190106022506-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 BLOOD TRANSFUSIONS ARE ASSOCIATED WITH MORTALITY IN PEDIATRIC PATIENTS WITH SYSTOLIC HEART FAILURE –�A MULTI-INSTITUTIONAL ANALYSIS - PCICS 2018 /slideshow/blood-transfusions-are-associated-with-mortality-in-pediatric-patients-with-systolic-heart-failure-a-multiinstitutional-analysis-pcics-2018/126850886 poster-181227173233
Restrictive thresholds for red blood cell (RBC) transfusion have not been shown to be inferior to liberal transfusion thresholds after cardiac surgery in pediatric or adult patients.1,2 RBC transfusions are associated with readmission due to heart failure (HF) in adults after aortic valve replacements, and with increased risk of right ventricle-pulmonary artery conduit failure in pediatric patients.3,4 Data are limited about RBC transfusions in pediatric patients with HF. ]]>
Restrictive thresholds for red blood cell (RBC) transfusion have not been shown to be inferior to liberal transfusion thresholds after cardiac surgery in pediatric or adult patients.1,2 RBC transfusions are associated with readmission due to heart failure (HF) in adults after aortic valve replacements, and with increased risk of right ventricle-pulmonary artery conduit failure in pediatric patients.3,4 Data are limited about RBC transfusions in pediatric patients with HF. ]]> Thu, 27 Dec 2018 17:32:33 GMT /slideshow/blood-transfusions-are-associated-with-mortality-in-pediatric-patients-with-systolic-heart-failure-a-multiinstitutional-analysis-pcics-2018/126850886 MarcAnders2@slideshare.net(MarcAnders2) BLOOD TRANSFUSIONS ARE ASSOCIATED WITH MORTALITY IN PEDIATRIC PATIENTS WITH SYSTOLIC HEART FAILURE –�A MULTI-INSTITUTIONAL ANALYSIS - PCICS 2018 MarcAnders2 Restrictive thresholds for red blood cell (RBC) transfusion have not been shown to be inferior to liberal transfusion thresholds after cardiac surgery in pediatric or adult patients.1,2 RBC transfusions are associated with readmission due to heart failure (HF) in adults after aortic valve replacements, and with increased risk of right ventricle-pulmonary artery conduit failure in pediatric patients.3,4 Data are limited about RBC transfusions in pediatric patients with HF. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/poster-181227173233-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Restrictive thresholds for red blood cell (RBC) transfusion have not been shown to be inferior to liberal transfusion thresholds after cardiac surgery in pediatric or adult patients.1,2 RBC transfusions are associated with readmission due to heart failure (HF) in adults after aortic valve replacements, and with increased risk of right ventricle-pulmonary artery conduit failure in pediatric patients.3,4 Data are limited about RBC transfusions in pediatric patients with HF.
BLOOD TRANSFUSIONS ARE ASSOCIATED WITH MORTALITY IN PEDIATRIC PATIENTS WITH SYSTOLIC HEART FAILURE – A MULTI-INSTITUTIONAL ANALYSIS - PCICS 2018 from Texas Children's Hospital
]]> 103 3 https://cdn.slidesharecdn.com/ss_thumbnails/poster-181227173233-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Diagnostic dilemma in tachycardiomyopathy - PCICS 2018 /slideshow/diagnostic-dilemma-in-tachycardiomyopathy-pcics-2018/126850473 diagnosticdilemmaintachycardiomyopathy-181227172556
Ectopic atrial tachycardia (EAT) is one of the most common forms of persistent supraventricular tachycardia in children. •  EAT is due to increased automaticity of a non-sinus atrial focus, and when leIt untreated can cause tachycardia-induced cardiomyopathy, also known as tachycardiomyopathy (TCMP). •  EAT can be difficult to distinguish from sinus tachycardia depending on the location of the ectopic focus. ]]>
Ectopic atrial tachycardia (EAT) is one of the most common forms of persistent supraventricular tachycardia in children. •  EAT is due to increased automaticity of a non-sinus atrial focus, and when leIt untreated can cause tachycardia-induced cardiomyopathy, also known as tachycardiomyopathy (TCMP). •  EAT can be difficult to distinguish from sinus tachycardia depending on the location of the ectopic focus. ]]> Thu, 27 Dec 2018 17:25:56 GMT /slideshow/diagnostic-dilemma-in-tachycardiomyopathy-pcics-2018/126850473 MarcAnders2@slideshare.net(MarcAnders2) Diagnostic dilemma in tachycardiomyopathy - PCICS 2018 MarcAnders2 Ectopic atrial tachycardia (EAT) is one of the most common forms of persistent supraventricular tachycardia in children. •  EAT is due to increased automaticity of a non-sinus atrial focus, and when leIt untreated can cause tachycardia-induced cardiomyopathy, also known as tachycardiomyopathy (TCMP). •  EAT can be difficult to distinguish from sinus tachycardia depending on the location of the ectopic focus. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/diagnosticdilemmaintachycardiomyopathy-181227172556-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Ectopic atrial tachycardia (EAT) is one of the most common forms of persistent supraventricular tachycardia in children. •  EAT is due to increased automaticity of a non-sinus atrial focus, and when leIt untreated can cause tachycardia-induced cardiomyopathy, also known as tachycardiomyopathy (TCMP). •  EAT can be difficult to distinguish from sinus tachycardia depending on the location of the ectopic focus.
Diagnostic dilemma in tachycardiomyopathy - PCICS 2018 from Texas Children's Hospital
]]> 88 1 https://cdn.slidesharecdn.com/ss_thumbnails/diagnosticdilemmaintachycardiomyopathy-181227172556-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Challenges in managing metabolic crises and arrhythmias in TANGO2 mutation - PCICS 2018 /slideshow/challenges-in-managing-metabolic-crises-and-arrhythmias-in-tango2-mutation-pcics-2018/126318963 tango2-181220022848
Challenges in managing metabolic crises and arrhythmias in TANGO2 mutation TANGO2 mutation is a rare genetic mutation characterized by metabolic crises associated with rhabdomyolysis, hypoglycemia, metabolic acidosis, encephalopathy, and life-threatening arrhythmias. There is a paucity of literature regarding the prevention or acute management of these metabolic crises and their sequelae ]]>
Challenges in managing metabolic crises and arrhythmias in TANGO2 mutation TANGO2 mutation is a rare genetic mutation characterized by metabolic crises associated with rhabdomyolysis, hypoglycemia, metabolic acidosis, encephalopathy, and life-threatening arrhythmias. There is a paucity of literature regarding the prevention or acute management of these metabolic crises and their sequelae ]]> Thu, 20 Dec 2018 02:28:48 GMT /slideshow/challenges-in-managing-metabolic-crises-and-arrhythmias-in-tango2-mutation-pcics-2018/126318963 MarcAnders2@slideshare.net(MarcAnders2) Challenges in managing metabolic crises and arrhythmias in TANGO2 mutation - PCICS 2018 MarcAnders2 Challenges in managing metabolic crises and arrhythmias in TANGO2 mutation TANGO2 mutation is a rare genetic mutation characterized by metabolic crises associated with rhabdomyolysis, hypoglycemia, metabolic acidosis, encephalopathy, and life-threatening arrhythmias. There is a paucity of literature regarding the prevention or acute management of these metabolic crises and their sequelae <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/tango2-181220022848-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Challenges in managing metabolic crises and arrhythmias in TANGO2 mutation TANGO2 mutation is a rare genetic mutation characterized by metabolic crises associated with rhabdomyolysis, hypoglycemia, metabolic acidosis, encephalopathy, and life-threatening arrhythmias. There is a paucity of literature regarding the prevention or acute management of these metabolic crises and their sequelae
Challenges in managing metabolic crises and arrhythmias in TANGO2 mutation - PCICS 2018 from Texas Children's Hospital
]]> 84 1 https://cdn.slidesharecdn.com/ss_thumbnails/tango2-181220022848-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Epidemiology of Pediatric Heart Failure in the US - PCICS 2018 /slideshow/epidemiology-of-pediatric-heart-failure-in-the-us-pcics-2018/126273607 pcicsposter-181219125426
As surgical and medical outcomes of children with congenital heart disease improve, it is expected that the pediatric population with heart failure (HF) will increase. To describe the characteristics and inpatient outcomes of HF patients across USA Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: January 2004 - December 2017 Inclusion criteria: All HF ICD 9/10 codes in patients ≤ 21 y/o from 50 different hospitals across USA ]]>
As surgical and medical outcomes of children with congenital heart disease improve, it is expected that the pediatric population with heart failure (HF) will increase. To describe the characteristics and inpatient outcomes of HF patients across USA Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: January 2004 - December 2017 Inclusion criteria: All HF ICD 9/10 codes in patients ≤ 21 y/o from 50 different hospitals across USA ]]> Wed, 19 Dec 2018 12:54:26 GMT /slideshow/epidemiology-of-pediatric-heart-failure-in-the-us-pcics-2018/126273607 MarcAnders2@slideshare.net(MarcAnders2) Epidemiology of Pediatric Heart Failure in the US - PCICS 2018 MarcAnders2 As surgical and medical outcomes of children with congenital heart disease improve, it is expected that the pediatric population with heart failure (HF) will increase. To describe the characteristics and inpatient outcomes of HF patients across USA Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: January 2004 - December 2017 Inclusion criteria: All HF ICD 9/10 codes in patients ≤ 21 y/o from 50 different hospitals across USA <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pcicsposter-181219125426-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> As surgical and medical outcomes of children with congenital heart disease improve, it is expected that the pediatric population with heart failure (HF) will increase. To describe the characteristics and inpatient outcomes of HF patients across USA Type of study: Retrospective cohort study Database: Pediatric Health Information System Study period: January 2004 - December 2017 Inclusion criteria: All HF ICD 9/10 codes in patients ≤ 21 y/o from 50 different hospitals across USA
Epidemiology of Pediatric Heart Failure in the US - PCICS 2018 from Texas Children's Hospital
]]> 114 1 https://cdn.slidesharecdn.com/ss_thumbnails/pcicsposter-181219125426-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Contributors, complications, and causative factors for central venous catheter-related deep vein thrombosis in critically ill children with congenital heart disease - PCICS 2018 /slideshow/contributors-complications-and-causative-factors-for-central-venous-catheterrelated-deep-vein-thrombosis-in-critically-ill-children-with-congenital-heart-disease-pcics-2018/126272406 pcicsdvtcvcposterfinalehs-181219122415
Central venous catheter (CVC) use is common in the management of critically ill children, especially those with congenital or acquired heart disease (CHD). Prior studies suggest that the presence of a CVC augments the risk of deep vein thrombosis (DVT) in adults and children. In recent years, the reported incidence of VTE in children has increased dramatically. How CVC-associated DVTs contribute to morbidity and mortality in this high risk patient population is unknown]]>
Central venous catheter (CVC) use is common in the management of critically ill children, especially those with congenital or acquired heart disease (CHD). Prior studies suggest that the presence of a CVC augments the risk of deep vein thrombosis (DVT) in adults and children. In recent years, the reported incidence of VTE in children has increased dramatically. How CVC-associated DVTs contribute to morbidity and mortality in this high risk patient population is unknown]]> Wed, 19 Dec 2018 12:24:15 GMT /slideshow/contributors-complications-and-causative-factors-for-central-venous-catheterrelated-deep-vein-thrombosis-in-critically-ill-children-with-congenital-heart-disease-pcics-2018/126272406 MarcAnders2@slideshare.net(MarcAnders2) Contributors, complications, and causative factors for central venous catheter-related deep vein thrombosis in critically ill children with congenital heart disease - PCICS 2018 MarcAnders2 Central venous catheter (CVC) use is common in the management of critically ill children, especially those with congenital or acquired heart disease (CHD). Prior studies suggest that the presence of a CVC augments the risk of deep vein thrombosis (DVT) in adults and children. In recent years, the reported incidence of VTE in children has increased dramatically. How CVC-associated DVTs contribute to morbidity and mortality in this high risk patient population is unknown <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pcicsdvtcvcposterfinalehs-181219122415-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Central venous catheter (CVC) use is common in the management of critically ill children, especially those with congenital or acquired heart disease (CHD). Prior studies suggest that the presence of a CVC augments the risk of deep vein thrombosis (DVT) in adults and children. In recent years, the reported incidence of VTE in children has increased dramatically. How CVC-associated DVTs contribute to morbidity and mortality in this high risk patient population is unknown
Contributors, complications, and causative factors for central venous catheter-related deep vein thrombosis in critically ill children with congenital heart disease - PCICS 2018 from Texas Children's Hospital
]]> 125 2 https://cdn.slidesharecdn.com/ss_thumbnails/pcicsdvtcvcposterfinalehs-181219122415-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Characteristics and Outcomes of Pediatric Patients supported with Ventricular Assist Device - A multi institutional analysis /slideshow/characteristics-and-outcomes-of-pediatric-patients-supported-with-ventricular-assist-device-a-multi-institutional-analysis/94539301 kritiposterphisvadishlt4-180421030610
Ventricular assist devices (VADs) are being increasingly used to support children with end stage heart failure (HF) as a bridge to transplant or decision to candidacy, with a dramatic increase in the last decade The aims of this study are to review trends in admissions of pediatric patients supported with VADs at children’s hospitals in the U.S. over a ten-year period, to assess rates of major complications in these patients, and to identify risk factors for adverse outcomes Multicenter retrospective analysis of the Pediatric Hospitals Information System (PHIS) database from 2005 to 2015 Inclusion criteria: (i) Age < 21years, (ii) ICD-9 codes for VAD implantation Primary outcome: hospital mortality. Secondary outcomes: total hospital length of stay (LOS), total cost of services (RCC method) Categorical and continuous variables compared using χ2/ Fisher exact and nonparametric tests respectively Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering within hospitals - factors with p<0.2 on univariate analysis included in the initial multivariable model, and factors with p<0.05 retained in successive models Use of VADs in the pediatric population is continuing to increase over time, with a stable mortality and complication rate There is an increase in patients able to be discharged home with a VAD in place Clinical features including acute renal failure, liver congestion, sepsis, cerebrovascular accident and need for ECMO support continue to complicate peri-implant VAD support, and are associated with mortality VAD repair during the VAD implant admission is associated with longer length of stay and total cost, however was not associated with mortality ]]>
Ventricular assist devices (VADs) are being increasingly used to support children with end stage heart failure (HF) as a bridge to transplant or decision to candidacy, with a dramatic increase in the last decade The aims of this study are to review trends in admissions of pediatric patients supported with VADs at children’s hospitals in the U.S. over a ten-year period, to assess rates of major complications in these patients, and to identify risk factors for adverse outcomes Multicenter retrospective analysis of the Pediatric Hospitals Information System (PHIS) database from 2005 to 2015 Inclusion criteria: (i) Age < 21years, (ii) ICD-9 codes for VAD implantation Primary outcome: hospital mortality. Secondary outcomes: total hospital length of stay (LOS), total cost of services (RCC method) Categorical and continuous variables compared using χ2/ Fisher exact and nonparametric tests respectively Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering within hospitals - factors with p<0.2 on univariate analysis included in the initial multivariable model, and factors with p<0.05 retained in successive models Use of VADs in the pediatric population is continuing to increase over time, with a stable mortality and complication rate There is an increase in patients able to be discharged home with a VAD in place Clinical features including acute renal failure, liver congestion, sepsis, cerebrovascular accident and need for ECMO support continue to complicate peri-implant VAD support, and are associated with mortality VAD repair during the VAD implant admission is associated with longer length of stay and total cost, however was not associated with mortality ]]> Sat, 21 Apr 2018 03:06:10 GMT /slideshow/characteristics-and-outcomes-of-pediatric-patients-supported-with-ventricular-assist-device-a-multi-institutional-analysis/94539301 MarcAnders2@slideshare.net(MarcAnders2) Characteristics and Outcomes of Pediatric Patients supported with Ventricular Assist Device - A multi institutional analysis MarcAnders2 Ventricular assist devices (VADs) are being increasingly used to support children with end stage heart failure (HF) as a bridge to transplant or decision to candidacy, with a dramatic increase in the last decade The aims of this study are to review trends in admissions of pediatric patients supported with VADs at children’s hospitals in the U.S. over a ten-year period, to assess rates of major complications in these patients, and to identify risk factors for adverse outcomes Multicenter retrospective analysis of the Pediatric Hospitals Information System (PHIS) database from 2005 to 2015 Inclusion criteria: (i) Age < 21years, (ii) ICD-9 codes for VAD implantation Primary outcome: hospital mortality. Secondary outcomes: total hospital length of stay (LOS), total cost of services (RCC method) Categorical and continuous variables compared using χ2/ Fisher exact and nonparametric tests respectively Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering within hospitals - factors with p<0.2 on univariate analysis included in the initial multivariable model, and factors with p<0.05 retained in successive models Use of VADs in the pediatric population is continuing to increase over time, with a stable mortality and complication rate There is an increase in patients able to be discharged home with a VAD in place Clinical features including acute renal failure, liver congestion, sepsis, cerebrovascular accident and need for ECMO support continue to complicate peri-implant VAD support, and are associated with mortality VAD repair during the VAD implant admission is associated with longer length of stay and total cost, however was not associated with mortality <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/kritiposterphisvadishlt4-180421030610-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Ventricular assist devices (VADs) are being increasingly used to support children with end stage heart failure (HF) as a bridge to transplant or decision to candidacy, with a dramatic increase in the last decade The aims of this study are to review trends in admissions of pediatric patients supported with VADs at children’s hospitals in the U.S. over a ten-year period, to assess rates of major complications in these patients, and to identify risk factors for adverse outcomes Multicenter retrospective analysis of the Pediatric Hospitals Information System (PHIS) database from 2005 to 2015 Inclusion criteria: (i) Age &lt; 21years, (ii) ICD-9 codes for VAD implantation Primary outcome: hospital mortality. Secondary outcomes: total hospital length of stay (LOS), total cost of services (RCC method) Categorical and continuous variables compared using χ2/ Fisher exact and nonparametric tests respectively Univariate and multivariable analyses performed using generalized estimating equations (GEE) for categorical outcomes and mixed modeling for continuous outcomes, to account for clustering within hospitals - factors with p&lt;0.2 on univariate analysis included in the initial multivariable model, and factors with p&lt;0.05 retained in successive models Use of VADs in the pediatric population is continuing to increase over time, with a stable mortality and complication rate There is an increase in patients able to be discharged home with a VAD in place Clinical features including acute renal failure, liver congestion, sepsis, cerebrovascular accident and need for ECMO support continue to complicate peri-implant VAD support, and are associated with mortality VAD repair during the VAD implant admission is associated with longer length of stay and total cost, however was not associated with mortality
Characteristics and Outcomes of Pediatric Patients supported with Ventricular Assist Device - A multi institutional analysis from Texas Children's Hospital
]]> 131 4 https://cdn.slidesharecdn.com/ss_thumbnails/kritiposterphisvadishlt4-180421030610-thumbnail.jpg?width=120&height=120&fit=bounds infographic Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The Significance of Bacterial and Fungal Coinfection in the Setting of Viral Pneumonia in Pediatric Patients on ECMO /slideshow/the-significance-of-bacterial-and-fungal-coinfection-in-the-setting-of-viral-pneumonia-in-pediatric-patients-on-ecmo/92830016 keystonecoinfectionscoleman2-180404000255
Keystone ECMO meeting 2018: To better characterize the frequency of bacterial and/or fungal coinfections in patients with viral pneumonias placed on ECMO and to understand their impact on mortality.]]>
Keystone ECMO meeting 2018: To better characterize the frequency of bacterial and/or fungal coinfections in patients with viral pneumonias placed on ECMO and to understand their impact on mortality.]]> Wed, 04 Apr 2018 00:02:54 GMT /slideshow/the-significance-of-bacterial-and-fungal-coinfection-in-the-setting-of-viral-pneumonia-in-pediatric-patients-on-ecmo/92830016 MarcAnders2@slideshare.net(MarcAnders2) The Significance of Bacterial and Fungal Coinfection in the Setting of Viral Pneumonia in Pediatric Patients on ECMO MarcAnders2 Keystone ECMO meeting 2018: To better characterize the frequency of bacterial and/or fungal coinfections in patients with viral pneumonias placed on ECMO and to understand their impact on mortality. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/keystonecoinfectionscoleman2-180404000255-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Keystone ECMO meeting 2018: To better characterize the frequency of bacterial and/or fungal coinfections in patients with viral pneumonias placed on ECMO and to understand their impact on mortality.
The Significance of Bacterial and Fungal Coinfection in the Setting of Viral Pneumonia in Pediatric Patients on ECMO from Texas Children's Hospital
]]> 54 4 https://cdn.slidesharecdn.com/ss_thumbnails/keystonecoinfectionscoleman2-180404000255-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Pediatric Patients with Viral Pneumonia Placed on ECMO /slideshow/pediatric-patients-with-viral-pneumonia-placed-on-ecmo/92829881 keystoneviralpnachartan-180403235919
Keystone ECMO meeting 2018: To review the characteristics and outcomes of pediatric patients with viral pneumonia placed on ECMO whose data were entered into the Extracorporeal Life Support Organization (ELSO) registry. ]]>
Keystone ECMO meeting 2018: To review the characteristics and outcomes of pediatric patients with viral pneumonia placed on ECMO whose data were entered into the Extracorporeal Life Support Organization (ELSO) registry. ]]> Tue, 03 Apr 2018 23:59:19 GMT /slideshow/pediatric-patients-with-viral-pneumonia-placed-on-ecmo/92829881 MarcAnders2@slideshare.net(MarcAnders2) Pediatric Patients with Viral Pneumonia Placed on ECMO MarcAnders2 Keystone ECMO meeting 2018: To review the characteristics and outcomes of pediatric patients with viral pneumonia placed on ECMO whose data were entered into the Extracorporeal Life Support Organization (ELSO) registry. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/keystoneviralpnachartan-180403235919-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Keystone ECMO meeting 2018: To review the characteristics and outcomes of pediatric patients with viral pneumonia placed on ECMO whose data were entered into the Extracorporeal Life Support Organization (ELSO) registry.
Pediatric Patients with Viral Pneumonia Placed on ECMO from Texas Children's Hospital
]]> 87 1 https://cdn.slidesharecdn.com/ss_thumbnails/keystoneviralpnachartan-180403235919-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 A multicenter cohort review of antithrombin use in pediatric patients with ventricular assist device /MarcAnders2/a-multicenter-cohort-review-of-antithrombin-use-in-pediatric-patients-with-ventricular-assist-device amulticentercohortreviewofantithrombinuseinpediatricpatientswithvad-171212072332
PCICS 2017 Describes the use of Antithrombin in pediatric patients with ventricular assist device (VAD)]]>
PCICS 2017 Describes the use of Antithrombin in pediatric patients with ventricular assist device (VAD)]]> Tue, 12 Dec 2017 07:23:32 GMT /MarcAnders2/a-multicenter-cohort-review-of-antithrombin-use-in-pediatric-patients-with-ventricular-assist-device MarcAnders2@slideshare.net(MarcAnders2) A multicenter cohort review of antithrombin use in pediatric patients with ventricular assist device MarcAnders2 PCICS 2017 Describes the use of Antithrombin in pediatric patients with ventricular assist device (VAD) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/amulticentercohortreviewofantithrombinuseinpediatricpatientswithvad-171212072332-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> PCICS 2017 Describes the use of Antithrombin in pediatric patients with ventricular assist device (VAD)
A multicenter cohort review of antithrombin use in pediatric patients with ventricular assist device from Texas Children's Hospital
]]> 63 1 https://cdn.slidesharecdn.com/ss_thumbnails/amulticentercohortreviewofantithrombinuseinpediatricpatientswithvad-171212072332-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Percutaneous VAD in children supported with ECMO for cardiogenic shock /slideshow/percutaneous-vad-in-children-supported-with-ecmo-for-cardiogenic-shock/79402253 imepllaecmoexpereinceposterforacure2017-170904045955
2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting. The Impella ventricular assist device support experience at Texas Children's Hospital.]]>
2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting. The Impella ventricular assist device support experience at Texas Children's Hospital.]]> Mon, 04 Sep 2017 04:59:55 GMT /slideshow/percutaneous-vad-in-children-supported-with-ecmo-for-cardiogenic-shock/79402253 MarcAnders2@slideshare.net(MarcAnders2) Percutaneous VAD in children supported with ECMO for cardiogenic shock MarcAnders2 2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting. The Impella ventricular assist device support experience at Texas Children's Hospital. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/imepllaecmoexpereinceposterforacure2017-170904045955-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> 2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting. The Impella ventricular assist device support experience at Texas Children&#39;s Hospital.
Percutaneous VAD in children supported with ECMO for cardiogenic shock from Texas Children's Hospital
]]> 106 2 https://cdn.slidesharecdn.com/ss_thumbnails/imepllaecmoexpereinceposterforacure2017-170904045955-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Anticoagulation in pediatric ventricular assist device - WCPCCS 2017 /slideshow/anticoagulation-in-pediatric-ventricular-assist-device-wcpccs-2017/78174401 antithrombotictherapyinchildren1-170723214131
Lack of standardization in ventricular assist device [VAD] - Does it matter ?]]>
Lack of standardization in ventricular assist device [VAD] - Does it matter ?]]> Sun, 23 Jul 2017 21:41:31 GMT /slideshow/anticoagulation-in-pediatric-ventricular-assist-device-wcpccs-2017/78174401 MarcAnders2@slideshare.net(MarcAnders2) Anticoagulation in pediatric ventricular assist device - WCPCCS 2017 MarcAnders2 Lack of standardization in ventricular assist device [VAD] - Does it matter ? <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/antithrombotictherapyinchildren1-170723214131-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Lack of standardization in ventricular assist device [VAD] - Does it matter ?
Anticoagulation in pediatric ventricular assist device - WCPCCS 2017 from Texas Children's Hospital
]]> 323 4 https://cdn.slidesharecdn.com/ss_thumbnails/antithrombotictherapyinchildren1-170723214131-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Extracorporeal Cardiopulmonary Resuscitation (ECPR) for fulminant portopulmonary Hypertension after Liver Transplantation - ANZICS 2013 /slideshow/extracorporeal-cardiopulmonary-resuscitation-ecpr-for-fuliminant-portopulmonary-hypertension-after-liver-transplantation/77492996 anzics2013pphtnref8163postera0v8b-170704085200
We report a 7-year-old girl who underwent orthotopic liver transplantation (OLT) for biliary atresia, and 5 days later had worsening suprasystemic pulmonary hypertension precipitating an asystolic arrest. She received cardiopulmonary resuscitation, followed by extracorporeal life support (ECLS). ANZICS 2013]]>
We report a 7-year-old girl who underwent orthotopic liver transplantation (OLT) for biliary atresia, and 5 days later had worsening suprasystemic pulmonary hypertension precipitating an asystolic arrest. She received cardiopulmonary resuscitation, followed by extracorporeal life support (ECLS). ANZICS 2013]]> Tue, 04 Jul 2017 08:52:00 GMT /slideshow/extracorporeal-cardiopulmonary-resuscitation-ecpr-for-fuliminant-portopulmonary-hypertension-after-liver-transplantation/77492996 MarcAnders2@slideshare.net(MarcAnders2) Extracorporeal Cardiopulmonary Resuscitation (ECPR) for fulminant portopulmonary Hypertension after Liver Transplantation - ANZICS 2013 MarcAnders2 We report a 7-year-old girl who underwent orthotopic liver transplantation (OLT) for biliary atresia, and 5 days later had worsening suprasystemic pulmonary hypertension precipitating an asystolic arrest. She received cardiopulmonary resuscitation, followed by extracorporeal life support (ECLS). ANZICS 2013 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/anzics2013pphtnref8163postera0v8b-170704085200-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> We report a 7-year-old girl who underwent orthotopic liver transplantation (OLT) for biliary atresia, and 5 days later had worsening suprasystemic pulmonary hypertension precipitating an asystolic arrest. She received cardiopulmonary resuscitation, followed by extracorporeal life support (ECLS). ANZICS 2013
Extracorporeal Cardiopulmonary Resuscitation (ECPR) for fulminant portopulmonary Hypertension after Liver Transplantation - ANZICS 2013 from Texas Children's Hospital
]]> 94 4 https://cdn.slidesharecdn.com/ss_thumbnails/anzics2013pphtnref8163postera0v8b-170704085200-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 PICU cardiac guide - PICUDoctor.org /slideshow/picu-cardiac-guide-picudoctororg/77332820 picuguide-170628103004
PICUDoctor.org is a medical reference e-book that covers the evolving knowledge in physiology and pathophysiology of pediatric cardiac critical care. From preoperative, perioperative and postoperative management through specific topics in critical care treatment, anaesthesia and analgesia, pharmacokinetics and pharmacodynamics, heart failure, circulatory mechanical assist and ECMO, the electronic format of PICUDoctor.org incorporates and allows implementation of up to date knowledge with multimedia. PICUDoctor.org was first developed in 2011 with contributions from authors around the world. Further edits and the transition to an online e-book followed in 2013 and 2014. Initially a bedside tool, it evolved into a full reference e-textbook with multiple multi-media functions as well as links to PubMed® articles to further support the users’ education. PICUDoctor.org is a not peer reviewed, but open source. To limit costs for publication and distribution, PICUdoctor.org is available in portable document format, iTunes and Google https://www.facebook.com/picudoctor.org/ for more details.]]>
PICUDoctor.org is a medical reference e-book that covers the evolving knowledge in physiology and pathophysiology of pediatric cardiac critical care. From preoperative, perioperative and postoperative management through specific topics in critical care treatment, anaesthesia and analgesia, pharmacokinetics and pharmacodynamics, heart failure, circulatory mechanical assist and ECMO, the electronic format of PICUDoctor.org incorporates and allows implementation of up to date knowledge with multimedia. PICUDoctor.org was first developed in 2011 with contributions from authors around the world. Further edits and the transition to an online e-book followed in 2013 and 2014. Initially a bedside tool, it evolved into a full reference e-textbook with multiple multi-media functions as well as links to PubMed® articles to further support the users’ education. PICUDoctor.org is a not peer reviewed, but open source. To limit costs for publication and distribution, PICUdoctor.org is available in portable document format, iTunes and Google https://www.facebook.com/picudoctor.org/ for more details.]]> Wed, 28 Jun 2017 10:30:04 GMT /slideshow/picu-cardiac-guide-picudoctororg/77332820 MarcAnders2@slideshare.net(MarcAnders2) PICU cardiac guide - PICUDoctor.org MarcAnders2 PICUDoctor.org is a medical reference e-book that covers the evolving knowledge in physiology and pathophysiology of pediatric cardiac critical care. From preoperative, perioperative and postoperative management through specific topics in critical care treatment, anaesthesia and analgesia, pharmacokinetics and pharmacodynamics, heart failure, circulatory mechanical assist and ECMO, the electronic format of PICUDoctor.org incorporates and allows implementation of up to date knowledge with multimedia. PICUDoctor.org was first developed in 2011 with contributions from authors around the world. Further edits and the transition to an online e-book followed in 2013 and 2014. Initially a bedside tool, it evolved into a full reference e-textbook with multiple multi-media functions as well as links to PubMed® articles to further support the users’ education. PICUDoctor.org is a not peer reviewed, but open source. To limit costs for publication and distribution, PICUdoctor.org is available in portable document format, iTunes and Google https://www.facebook.com/picudoctor.org/ for more details. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/picuguide-170628103004-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> PICUDoctor.org is a medical reference e-book that covers the evolving knowledge in physiology and pathophysiology of pediatric cardiac critical care. From preoperative, perioperative and postoperative management through specific topics in critical care treatment, anaesthesia and analgesia, pharmacokinetics and pharmacodynamics, heart failure, circulatory mechanical assist and ECMO, the electronic format of PICUDoctor.org incorporates and allows implementation of up to date knowledge with multimedia. PICUDoctor.org was first developed in 2011 with contributions from authors around the world. Further edits and the transition to an online e-book followed in 2013 and 2014. Initially a bedside tool, it evolved into a full reference e-textbook with multiple multi-media functions as well as links to PubMed® articles to further support the users’ education. PICUDoctor.org is a not peer reviewed, but open source. To limit costs for publication and distribution, PICUdoctor.org is available in portable document format, iTunes and Google https://www.facebook.com/picudoctor.org/ for more details.
PICU cardiac guide - PICUDoctor.org from Texas Children's Hospital
]]> 606 15 https://cdn.slidesharecdn.com/ss_thumbnails/picuguide-170628103004-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Extracorporeal Life Support (ECMO) prior Stage 1 surgical palliation in Hypoplastic Left Heart Syndrome - PICC 2016 /slideshow/extracorporeal-life-support-ecmo-prior-stage-1-surgical-palliation-in-hypoplastic-left-heart-syndrome/76611922 ecmohlhspostertoronto20161-170603085317
Explores the ESLO database for patients with Hypoplastic Left Heart Syndrome (HLHS) and ECMO requirement prior any surgical palliation in regards to outcome]]>
Explores the ESLO database for patients with Hypoplastic Left Heart Syndrome (HLHS) and ECMO requirement prior any surgical palliation in regards to outcome]]> Sat, 03 Jun 2017 08:53:17 GMT /slideshow/extracorporeal-life-support-ecmo-prior-stage-1-surgical-palliation-in-hypoplastic-left-heart-syndrome/76611922 MarcAnders2@slideshare.net(MarcAnders2) Extracorporeal Life Support (ECMO) prior Stage 1 surgical palliation in Hypoplastic Left Heart Syndrome - PICC 2016 MarcAnders2 Explores the ESLO database for patients with Hypoplastic Left Heart Syndrome (HLHS) and ECMO requirement prior any surgical palliation in regards to outcome <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ecmohlhspostertoronto20161-170603085317-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Explores the ESLO database for patients with Hypoplastic Left Heart Syndrome (HLHS) and ECMO requirement prior any surgical palliation in regards to outcome
Extracorporeal Life Support (ECMO) prior Stage 1 surgical palliation in Hypoplastic Left Heart Syndrome - PICC 2016 from Texas Children's Hospital
]]> 145 2 https://cdn.slidesharecdn.com/ss_thumbnails/ecmohlhspostertoronto20161-170603085317-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Baylor Education Retreat Workshop - PICUDoctor - BCM 2016 /slideshow/baylor-education-retreat-workshop-picudoctor/76536737 picudocposter-170531195912
www.picudoctor.org]]>
www.picudoctor.org]]> Wed, 31 May 2017 19:59:12 GMT /slideshow/baylor-education-retreat-workshop-picudoctor/76536737 MarcAnders2@slideshare.net(MarcAnders2) Baylor Education Retreat Workshop - PICUDoctor - BCM 2016 MarcAnders2 www.picudoctor.org <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/picudocposter-170531195912-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> www.picudoctor.org
Baylor Education Retreat Workshop - PICUDoctor - BCM 2016 from Texas Children's Hospital
]]> 300 2 https://cdn.slidesharecdn.com/ss_thumbnails/picudocposter-170531195912-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-MarcAnders2-48x48.jpg?cb=1702656129 www.picudoctor.org https://cdn.slidesharecdn.com/ss_thumbnails/ishltposter-200626012455-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/anemia-is-associated-with-greater-morbidity-and-resource-utilization-in-pediatric-patients-with-systolic-heart-failure-a-multiinstitutional-analysis/236228267 ANEMIA IS ASSOCIATED W... https://cdn.slidesharecdn.com/ss_thumbnails/ppcmposterdraft2ma-190228185021-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/ecmo-in-peripartum-cardiomyopathy-an-elso-review/133728440 ECMO in peripartum car... https://cdn.slidesharecdn.com/ss_thumbnails/ivmeds-190221222259-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/use-of-inotropic-and-vasoconstrictor-medications-in-the-pediatric-heart-failure-population/132796111 Use of inotropic and v...